--- a
+++ b/clusters/9knumclustersv2/clust_1125.txt
@@ -0,0 +1,81 @@
+Uncontrolled or significant cardiovascular disease, clinically significant ventricular arrhythmia (such as ventricular tachycardia, ventricular fibrillation, or Torsades des pointes), clinically significant pulmonary disease (such as ? Grade  dyspnea, according to CTCAE .)
+History or presence of sustained ventricular tachycardia
+Any history of ventricular fibrillation or torsades de pointes
+Significant ventricular arrhythmia (persistent ventricular tachycardia, ventricular fibrillation, resuscitated sudden death)
+Persistent or clinically meaningful ventricular arrhythmias.
+Ventricular arrhythmias requiring continuous therapy, or
+A known history of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), Torsade de Pointes, or cardiac arrest unless currently addressed with an automatic implantable cardioverter defibrillator (AICD)
+Severe, active co-morbidity, defined as follows:\r\n* Cardiac symptoms; any of the following should be considered for exclusion:\r\n** Uncontrolled angina, congestive heart failure or myocardial infarction (MI) within ( months)\r\n** Diagnosed congenital long QT syndrome\r\n** Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes)\r\n** Prolonged corrected QT (QTc) interval on pre-entry electrocardiogram (>  msec)
+Patients with a known history of corrected QT (QTc) prolongation (>  msec), or known history of ventricular tachycardia, ventricular fibrillation or Torsades de pointes are not eligible
+Clinically significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to: any history of myocardial infarction (MI), stroke, or revascularization; unstable angina or transient ischemic attack prior to enrollment; congestive heart failure prior to enrollment, or left ventricular ejection fraction (LVEF) less than lower limit of normal per local institutional standards prior to enrollment; diagnosed or suspected congenital long QT syndrome; any history of clinically significant atrial or ventricular arrhythmias (such as artrial fibrillation, ventricular tachycardia, ventricular fibrillation, or Torsades de Pointes) as determined by the treating physician; prolonged QTc interval on pre-entry electrocardiogram (>  msec) unless corrected after electrolyte replacement.
+Clinically significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to: Any history of myocardial infarction (MI), stroke, or revascularization; Unstable angina or transient ischemic attack prior to enrollment; Congestive heart failure prior to enrollment, or left ventricular ejection fraction (LVEF) less than lower limit of normal per local institutional standards prior to enrollment; Diagnosed or suspected congenital long QT syndrome; Any history of clinically significant atrial or ventricular arrhythmias (such as atrial fibrillation, ventricular tachycardia, ventricular fibrillation, or Torsades de pointes) as determined by the treating physician; Prolonged QTc interval on pre-entry electrocardiogram (>  msec) unless corrected after electrolyte replacement. Any history of venous thromboembolism including deep venous thrombosis or pulmonary embolism; Uncontrolled hypertension (diastolic blood pressure >  mmHg; systolic >  mmHg). Patients with hypertension should be under treatment on study entry to effect blood pressure control.
+Class II or greater New York Heart Association Functional Classification criteria or serious cardiac arrhythmias likely to increase the risk of cardiac complications of cytokine therapy (e.g. ventricular tachycardia, frequent ventricular ectopy, or supraventricular tachyarrhythmia requiring chronic therapy)
+Participants with a history of sustained ventricular tachycardia or aborted ventricular fibrillation or with a history of atrioventricular (AV) nodal or sinoatrial (SA) nodal dysfunction for which a pacemaker/implantable cardioverter-defibrillators [ICD] is indicated but not placed (participants who do have a pacemaker/ICD are allowed on study)
+Uncontrolled or significant cardiovascular disease including, but not limited to, any of the following:\r\n* Myocardial infarction within the past  months \r\n* Uncontrolled angina within the past  months \r\n* Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation or Torsades de pointes); controlled atrial fibrillation by itself is not an exclusion criterion
+A known history of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), torsade de pointes, or cardiac arrest unless currently addressed with an automatic implantable cardioverter-defibrillator (AICD)
+Patients who currently have or have a history of the following within  months preceding study entry are not eligible: unstable angina (UA), myocardial infarction (MI), transient ischemic attack (TIA), stroke, deep vein thrombosis (DVT), acute peripheral or pulmonary arterial thromboembolism (PE); clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, or torsades de pointes); New York Heart Association class III or IV heart failure
+Any history of clinically significant ventricular arrhythmia (such as ventricular tachycardia, ventricular fibrillation or torsade de pointes)
+Significant cardiovascular disease, including:\r\n* Cardiac failure New York Heart Association (NYHA) class III or IV\r\n* Myocardial infarction, severe or unstable angina within  months prior to study day \r\n* History of serious arrhythmia (i.e., ventricular tachycardia, or ventricular fibrillation)\r\n* Ventricular cardiac arrhythmias requiring anti-arrhythmic medications\r\n* Known left ventricular ejection fraction (LVEF) =< %
+Uncontrolled or significant cardiovascular disease, clinically significant ventricular arrhythmia (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes), clinically significant pulmonary disease (such as ? Grade  dyspnea, according to CTCAE .).
+A known history of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), torsade de pointes, or cardiac arrest unless currently addressed with an automatic implantable cardioverter defibrillator (AICD)
+Current, serious, clinically significant cardiac arrhythmias, defined as the existence of an absolute arrhythmia or ventricular arrhythmias classified as Lown III, IV or V (Appendix F).
+History of sustained ventricular tachycardia
+Any history of ventricular fibrillation or torsades de pointes
+Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes)
+Concurrent medical condition which may increase the risk of toxicity, including:\r\n* Pleural or pericardial effusion of any grade at the time of screening for study\r\n* Cardiac symptoms; any of the following should be considered for exclusion:\r\n** Uncontrolled angina, congestive heart failure or myocardial infarction (MI) (within  months)\r\n** Diagnosed congenital long QT syndrome\r\n** Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de Pointes)\r\n** Prolonged corrected QT (QTc) interval on pre-entry electrocardiogram (>  msec)
+Cardiac disease including: uncontrolled angina within  months; diagnosed or suspected congenital long QT syndrome; any history of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, or Torsades de pointes); prolonged corrected QT (QTc) interval on pre-entry electrocardiogram (>  msec) on the Fridericia's correction; uncontrolled hypertension (defined for this protocol as sustained systolic blood pressure [BP] >=  and diastolic >= ); patients currently taking drugs that are generally accepted to have a risk of causing Torsades de pointes
+Clinically significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to: \r\n* Any history of myocardial infarction (MI), stroke, or revascularization\r\n* Unstable angina or transient ischemic attack prior to enrollment \r\n* Congestive heart failure prior to enrollment, or left ventricular ejection fraction (LVEF) less than lower limit of normal per local institutional standards prior to enrollment \r\n* Diagnosed or suspected congenital long QT syndrome \r\n* Any history of clinically significant atrial or ventricular arrhythmias (such as atrial fibrillation, ventricular tachycardia, ventricular fibrillation, or torsades de pointes) as determined by the treating physician\r\n* Prolonged corrected QT (QTc) interval on pre-entry electrocardiogram (>  msec) unless corrected after electrolyte replacement\r\n* Any history of venous thromboembolism including deep venous thrombosis or pulmonary embolism\r\n* Uncontrolled hypertension (diastolic blood pressure >  mmHg; systolic >  mmHg); patients with hypertension should be under treatment on study entry to effect blood pressure control
+History of clinically significant ventricular arrhythmias
+History of clinically significant ventricular arrhythmias (i.e., sustained ventricular tachycardia, ventricular fibrillation or Torsades de Pointes);
+Class II or greater New York Heart Association Functional Classification criteria or serious cardiac arrhythmias likely to increase the risk of cardiac complications of cytokine therapy (e.g. ventricular tachycardia, frequent ventricular ectopy, or supraventricular tachyarrhythmia requiring chronic therapy)
+Clinically significant cardiovascular disease including:\r\n* LVEF < % measured by echocardiogram\r\n* History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within  months\r\n* Uncontrolled angina within  months\r\n* New York Heart Association (NYHA) class III or IV congestive heart failure\r\n* Clinically significant abnormality on EKG\r\n* History of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes)\r\n* Patients with intra-cardiac defibrillators or permanent pacemakers
+History of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsade de pointes);
+Class II or greater congestive heart failure as described in the New York Heart Association Functional Classification criteria or serious arrhythmias likely to increase the risk of cardiac complications of cytokine therapy (e.g. ventricular tachycardia, frequent ventricular ectopy, or supraventricular tachyarrhythmias requiring chronic therapy)
+Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, congenital long QT syndrome, or torsades de pointes)
+Class II or greater New York Heart Association Functional Classification criteria or serious cardiac arrhythmias likely to increase the risk of cardiac complications of cytokine therapy (e.g. ventricular tachycardia, frequent ventricular ectopy, or supraventricular tachyarrhythmia requiring chronic therapy)
+Subject with clinically significant cardiac arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes, second degree or third degree atrioventricular heart block without a permanent pacemaker in place)
+Personal history of long QTc syndrome or ventricular arrhythmias including ventricular bigeminy.
+Uncontrolled or significant cardiovascular disease including, but not limited to, any of the following:\r\n* Myocardial infarction within the past  months\r\n* Uncontrolled angina within the past  months\r\n* Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation or Torsades de pointes); controlled atrial fibrillation by itself is not an exclusion criterion\r\n* Baseline corrected QT (QTc) interval greater than  milliseconds
+Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes)
+Have clinically significant cardiac disease (NYHA Class III or IV); clinically significant arrhythmia i.e. ventricular tachycardia, ventricular fibrillation, or \Torsade de Pointes\. Myocardial infarction with uncontrolled angina within  months, congestive heart failure, or clinical significant cardiomyopathy
+Patients who have any serious or uncontrolled medical disorder that would impair the ability of the subject to receive protocol therapy are not eligible; these include, but are not limited to: \r\n* Active infection that is not well controlled\r\n* Known pleural or pericardial effusion at baseline \r\n* Clinically significant gastrointestinal disease or digestive dysfunction compromising absorption of dasatinib\r\n* Pulmonary arterial hypertension \r\n* Uncontrolled or significant cardiovascular disease, including:\r\n** Myocardial infarction within  months of enrollment date\r\n** Uncontrolled angina or congestive heart failure within  months of enrollment date\r\n** Left ventricular ejection fraction (LVEF) < %\r\n** Significant cardiac conduction abnormality, including: \r\n*** History of clinically significant ventricular arrhythmia (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes)\r\n*** History of second or third degree heart block (except for second degree type )\r\n*** Corrected QT (QTc) interval >  msec, unless a cardiac pacemaker is present\r\n* Prior malignancy active within the previous  years, except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancers, superficial bladder cancer, or carcinoma in situ of the prostate, cervix or breast\r\n* Subjects with active, known or suspected autoimmune disease; (Note: Subjects with vitiligo, type I diabetes mellitus, hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll)\r\n* Psychiatric illness/social situations that would limit compliance with study requirements\r\n* Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patients safety or study endpoints
+Patients who currently have or have a history of the following within  months preceding study entry are not eligible: unstable angina (UA) or myocardial infarction (MI), clinically significant atrial or ventricular arrhythmias (e.g., atrial fibrillation [AF], atrial flutter, ventricular tachycardia, ventricular fibrillation, or torsades de pointes), New York Heart Association (NYHA) class III or IV heart failure
+History of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, Torsade de Pointes).
+Any of the following within  months before the first dose of study treatment:\r\n* Unstable angina pectoris\r\n* Clinically-significant cardiac arrhythmias\r\n* Stroke (including transient ischemic attack [TIA], or other ischemic event)\r\n* Myocardial infarction\r\n* Thromboembolic event requiring therapeutic anticoagulation (Note: subjects with a venous filter [e.g. vena cava filter] are not eligible for this study)\r\n* Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes)\r\n* Prolonged QTc interval on pre-entry electrocardiogram (>  msec), may use either the Fridericia and Bazetts correction\r\n* Hypokalemia or hypomagnesemia that is not corrected prior to dasatinib administration\r\n* Patients should not be taking drugs that are generally accepted to have a risk of causing torsades de pointes; the following must be discontinued at least  days prior to starting dasatinib to be eligible: quinidine, procainamide, disopyramide, amiodarone, sotalol, ibutilide, dofetilide, erythromycins, clarithromycin, chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide, cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine, sparfloxacin, lidoflazine
+A known history of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), torsade de pointes, or cardiac arrest unless currently addressed with an automatic implantable cardioverter defibrillator (AICD)
+Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, Wolff-Parkinson-White [WPW] syndrome, or torsade de pointes), or prolonged QTc interval on pre-entry ECG (> msec). If the automated reading is prolonged (i.e., > msec), the ECG should be manually over-read.
+No history of sustained ventricular tachycardia (lasting longer than  sec) or cardiac arrest
+Unacceptable cardiac risk factors defined by any of the following criteria: patients with congenital long QT syndrome, any history of ventricular fibrillation or torsade de pointes, bradycardia defined as heart rate (HR) <  bpm, left ventricular ejection fraction < %
+Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes);
+PART B: Any history of ventricular arrhythmia (other than premature ventricular complexes)
+Concurrent medical condition which may increase the risk of toxicity, including:\r\n* Pleural or pericardial effusion of any grade at the time of screening for study\r\n* Cardiac symptoms; any of the following should be considered for exclusion:\r\n** Uncontrolled angina, congestive heart failure or myocardial infarction (MI) within ( months)\r\n** Diagnosed congenital long QT syndrome\r\n** Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes)
+History of complex ventricular or supraventricular arrhythmias
+Any history of ventricular fibrillation or torsade de pointes
+History of clinically significant ventricular arrhythmias or active ventricular arrhythmia requiring medication
+High-risk uncontrolled arrhythmias (ventricular tachycardia, high-grade atrio-ventricular [AV]-block, supraventricular tachycardias which are not adequately rate-controlled)
+Any history of ventricular fibrillation or torsade de pointes
+History of Torsades de pointes, ventricular tachycardia, or ventricular fibrillation
+History of Torsades de pointes, ventricular tachycardia, or ventricular fibrillation
+Uncontrolled or significant cardiovascular disease, including:\r\n* A myocardial infarction within  months of registration\r\n* Uncontrolled angina within  months of registration\r\n* Congestive heart failure within  months of registration\r\n* Diagnosed or suspected congenital long QT syndrome\r\n* Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes)\r\n* Prolonged corrected QT (QTc) interval on pre-entry electrocardiogram (>  msec)\r\n* Any history of second or third degree heart block (may be eligible if currently have a pacemaker)\r\n* Heart rate < /minute on pre-entry electrocardiogram\r\n* Uncontrolled hypertension
+Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes)
+Active Grade III-V cardiac failure as defined by the New York Heart Association Criteria. Uncontrolled angina, or MI within  months. Diagnosed or suspected congenital long QT syndrome. Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes). Prolonged QTc interval on pre-entry electrocardiogram (>  msec). Patients currently taking drugs that are generally accepted to have a risk of causing Torsades de Pointes (unless these can be changed to acceptable alternatives)
+Persistent or clinically meaningful ventricular arrhythmias
+History of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes);
+Any of the following related to risk of torsades de pointes and sudden cardiac death:\r\n* History of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), torsades de pointes, or resuscitated cardiac arrest unless currently addressed with an implanted cardiac defibrillator\r\n* Concomitant treatment with an anti-arrhythmic agent to prevent or control arrhythmia; agents used for rate-control of atrial fibrillation are permitted provided that they are not prohibited due to potential drug interactions\r\n* Known congenital long QT syndrome\r\n* Second degree atrioventricular (AV) block type II, third degree AV block, or ventricular rate <  bpm or >  bpm
+Any history of ventricular fibrillation or torsade de pointes
+Any history of ventricular fibrillation or torsade de pointes.
+Current, serious, clinically significant cardiac arrhythmias, defined as the existence of an absolute arrhythmia or ventricular arrhythmias classified as Lown III, IV or V.
+History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation)
+A known history of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), torsade de pointes, or cardiac arrest unless currently addressed with an automatic implantable cardioverter defibrillator (AICD)
+Known history of sustained (>  second) ventricular tachycardia or cardiac syncope. Known history of recurrent non-sustained ventricular tachycardia (>  beats) despite anti-arrhythmic therapy
+History of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsade de pointes)
+Uncontrolled angina or uncontrolled hypertension or any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes)
+Patients meeting the following criteria are not eligible: history of unstable angina, myocardial infarction, transient ischemic attack (TIA), stroke, peripheral arterial occlusive disease, venous thromboembolism or pulmonary embolism; any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes); prolonged corrected QT (QTc) interval on pre-entry electrocardiogram (>  msec) on both the Fridericia and Bazetts correction; symptomatic congestive heart failure within  months prior to first dose of ponatinib (New York Heart Association [NYHA] class III or IV)
+Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de Pointes [TdP]);
+History of clinically relevant ventricular arrhythmias (eg, ventricular tachycardia, ventricular fibrillation, or Torsade de Pointes);
+History or presence of sustained ventricular tachycardia
+Any history of ventricular fibrillation or torsades de pointes
+Class II or greater New York Heart Association Functional Classification criteria or serious cardiac arrhythmias likely to increase the risk of cardiac complications of cytokine therapy (e.g. ventricular tachycardia, frequent ventricular ectopy, or supraventricular tachyarrhythmia requiring chronic therapy)
+Significant ventricular arrhythmias (>  premature ventricular contractions [PVCs]/min due to gating difficulty) atrial fibrillation with uncontrolled ventricular response
+Significant ventricular arrhythmias (>  premature ventricular contractions [PVCs]/minute due to gating difficulty)
+Patients with clinically unstable cardiac arrhythmias, such as recurrent ventricular tachycardia